Ketamine in adult super-refractory status epilepticus: Efficacy analysis on a prospective registry.

ABSTRACT:

Background

Status epilepticus (SE) persisting despite two anti-seizures medications (ASM) and anesthetics is labeled super refractory (SRSE), correlating with important morbidity and mortality. Its treatment relies on expert opinions. Due to its pharmacological properties, ketamine (KET) has received increasing attention, but data are essentially retrospective.

Aims

To describe an unselected cohort of adults receiving KET for SRSE.

Methods

Analysis of a prospective registry of consecutive SE episodes, identifying SRSE patients receiving ketamine (KET). Comparison with recent adult series including more than 10 patients.

Results

Eleven patients received KET after a median of 4 days (range: 2-20); median dose was 5 mg/kg/h (range: 2.5-15). KET provided permanent

SUBMITTER: Caranzano L 

PROVIDER: S-EPMC9310735 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature